Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GTHX NASDAQ:SDGR NASDAQ:SNDX NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/ASDGRSchrodinger$19.08-7.6%$19.56$16.60▼$28.47$1.52B1.741.09 million shs1.02 million shsSNDXSyndax Pharmaceuticals$16.06-0.9%$15.25$8.58▼$22.50$1.40B0.682.03 million shs2.70 million shsSTOKStoke Therapeutics$30.19+1.0%$20.97$5.35▼$32.40$1.64B1.241.23 million shs1.33 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHXG1 Therapeutics0.00%0.00%0.00%0.00%0.00%SDGRSchrodinger-7.60%-7.33%+5.12%-9.19%+10.80%SNDXSyndax Pharmaceuticals-0.86%+2.95%+2.10%+67.47%-12.34%STOKStoke Therapeutics+0.97%+18.11%+33.23%+154.55%+152.64%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/ASDGRSchrodinger$19.08-7.6%$19.56$16.60▼$28.47$1.52B1.741.09 million shs1.02 million shsSNDXSyndax Pharmaceuticals$16.06-0.9%$15.25$8.58▼$22.50$1.40B0.682.03 million shs2.70 million shsSTOKStoke Therapeutics$30.19+1.0%$20.97$5.35▼$32.40$1.64B1.241.23 million shs1.33 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGTHXG1 Therapeutics0.00%0.00%0.00%0.00%0.00%SDGRSchrodinger-7.60%-7.33%+5.12%-9.19%+10.80%SNDXSyndax Pharmaceuticals-0.86%+2.95%+2.10%+67.47%-12.34%STOKStoke Therapeutics+0.97%+18.11%+33.23%+154.55%+152.64%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGTHXG1 Therapeutics 0.00N/AN/AN/ASDGRSchrodinger 2.38Hold$26.2937.77% UpsideSNDXSyndax Pharmaceuticals 2.82Moderate Buy$39.22144.22% UpsideSTOKStoke Therapeutics 2.89Moderate Buy$27.43-9.15% DownsideCurrent Analyst Ratings BreakdownLatest GTHX, SDGR, STOK, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025STOKStoke TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $35.0010/8/2025SDGRSchrodingerKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$30.00 ➝ $28.0010/8/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025STOKStoke TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$19.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SNDXSyndax PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025STOKStoke TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/19/2025SNDXSyndax PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$56.009/10/2025SNDXSyndax PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51SDGRSchrodinger$207.54M6.77N/AN/A$5.78 per share3.30SNDXSyndax Pharmaceuticals$23.68M58.42N/AN/A$3.38 per share4.75STOKStoke Therapeutics$36.56M45.25N/AN/A$4.32 per share6.99Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/ASDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.89N/AN/AN/A-428.48%-130.47%-56.12%11/4/2025 (Estimated)STOKStoke Therapeutics-$88.98M$0.8535.52N/AN/A26.25%18.32%15.48%11/4/2025 (Estimated)Latest GTHX, SDGR, STOK, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025SNDXSyndax Pharmaceuticals-$0.73N/AN/AN/A$49.08 millionN/A11/4/2025Q3 2025STOKStoke Therapeutics-$0.56N/AN/AN/AN/AN/A8/12/2025Q2 2025STOKStoke Therapeutics-$0.57-$0.40+$0.17-$0.40$31.51 million$13.82 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025SNDXSyndax Pharmaceuticals-$1.01-$0.83+$0.18-$0.83$26.64 million$37.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGTHXG1 TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGTHXG1 Therapeutics1.342.482.12SDGRSchrodingerN/A3.303.30SNDXSyndax Pharmaceuticals2.064.714.55STOKStoke TherapeuticsN/A6.986.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGTHXG1 Therapeutics24.21%SDGRSchrodinger79.05%SNDXSyndax PharmaceuticalsN/ASTOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipGTHXG1 Therapeutics6.11%SDGRSchrodinger21.00%SNDXSyndax Pharmaceuticals4.10%STOKStoke Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableSNDXSyndax Pharmaceuticals11086.14 million82.61 millionOptionableSTOKStoke Therapeutics10054.80 million49.59 millionOptionableGTHX, SDGR, STOK, and SNDX HeadlinesRecent News About These CompaniesStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Needham & Company LLC5 hours ago | marketbeat.comNeedham Maintains Stoke Therapeutics (STOK) Buy RecommendationOctober 10 at 6:30 PM | msn.comWhat 4 Analyst Ratings Have To Say About Stoke TherapeuticsOctober 10 at 6:30 PM | benzinga.comStoke Therapeutics price target raised to $35 from $22 at NeedhamOctober 10 at 1:30 PM | msn.comBiogen, Stoke Therapeutics present follow-up analyses from zorevunersen studiesOctober 10 at 8:29 AM | msn.comWhy Stoke Therapeutics (STOK) Is Up 20.5% After Zorevunersen Data Shows Sustained Benefits in Dravet SyndromeOctober 10 at 8:29 AM | finance.yahoo.comWhat is Leerink Partnrs' Estimate for STOK FY2027 Earnings?October 10 at 8:15 AM | marketbeat.comBiogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9 at 8:04 PM | markets.businessinsider.comStoke, Biogen presents new data from OLE studies of zorevunersenOctober 9 at 8:04 PM | msn.comStoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying ...October 9 at 8:04 PM | finance.yahoo.comStoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?October 9 at 10:25 AM | zacks.comStoke Therapeutics (NASDAQ:STOK) Given "Sell (D+)" Rating at Weiss RatingsOctober 9 at 2:27 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Sees Unusually-High Trading Volume - Here's WhyOctober 8 at 2:10 PM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Sells $250,700.00 in StockOctober 8 at 5:21 AM | insidertrades.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from AnalystsOctober 8 at 2:55 AM | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of "Buy" from AnalystsOctober 8 at 2:54 AM | marketbeat.comStoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 10,000 SharesOctober 7, 2025 | marketbeat.comStoke Therapeutics (NASDAQ:STOK) Director Sells 42,461 SharesOctober 7, 2025 | marketbeat.comStoke Therapeutics stock rises after appointing Ian Smith as CEOOctober 6, 2025 | investing.comStoke Therapeutics Appoints Smith as Permanent CEOOctober 6, 2025 | marketwatch.comStoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High - Still a Buy?October 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGTHX, SDGR, STOK, and SNDX Company DescriptionsG1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Schrodinger NASDAQ:SDGR$19.08 -1.57 (-7.60%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$18.90 -0.18 (-0.97%) As of 10/10/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.Syndax Pharmaceuticals NASDAQ:SNDX$16.06 -0.14 (-0.86%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$15.94 -0.11 (-0.72%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Stoke Therapeutics NASDAQ:STOK$30.19 +0.29 (+0.97%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$29.32 -0.87 (-2.87%) As of 10/10/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
